title: Chlorpromazine-induced inhibition of catecholamine secretion by a differential blockade of nicotinic receptors and L-type Ca2+ channels in rat pheochromocytoma cells.
abstract: We investigated the effect of chlorpromazine (CPZ), a phenothiazine neuroleptic, on catecholamine secretion in rat pheochromocytoma (PC12) cells. CPZ inhibited [3H]norepinephrine ([3H]NE) secretion induced by 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), an agonist of nicotinic acetylcholine receptors (nAChRs) with an IC50 value of 1.0 +/- 0.2 microM. The DMPP-induced rise in cytosolic free Ca2+ concentration [Ca2+]i was inhibited by CPZ with an IC50 of 1.9 +/- 0.1 microM. The DMPP-induced increase in cytosolic free Na+ concentration [Na+]i was also inhibited by CPZ with a similar potency. Furthermore, the binding of [3H]nicotine to PC12 cells was inhibited by CPZ with an IC50 value of 2.7 +/- 0.6 microM, suggesting that the nAChRs themselves are inhibited by CPZ. In addition, both 70 mM K+-induced [3H]NE secretion and [Ca2+]i increase were inhibited by CPZ with IC50 of 7.9 +/- 1.1 and 6.2 +/- 0.3 microM, respectively. Experiments with Ca2+ channel antagonists suggest that L-type Ca2+ channels are mainly responsible for the inhibition. We conclude that CPZ inhibits catecholamine secretion by blocking nAChRs and L-type Ca2+ channels, with the former being more sensitive to CPZ.
authors.affiliation: Department of Life Science, Pohang University of Science and Technology, Korea.
authors.forename: I S
authors.initials: IS
authors.lastname: Lee
authors.forename: T J
authors.initials: TJ
authors.lastname: Park
authors.forename: B C
authors.initials: BC
authors.lastname: Suh
authors.forename: Y S
authors.initials: YS
authors.lastname: Kim
authors.forename: I J
authors.initials: IJ
authors.lastname: Rhee
authors.forename: K T
authors.initials: KT
authors.lastname: Kim
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000378:metabolism; D020746:Calcium Channels, L-Type; D002395:Catecholamines / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology*; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D016716:PC12 Cells; D011188:Potassium / Q000378:metabolism; D051381:Rats; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D002395:Catecholamines; D018492:Dopamine Antagonists; D018733:Nicotinic Antagonists; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D014316:Tritium; D004246:Dimethylphenylpiperazinium Iodide; D011188:Potassium; D001920:Bradykinin; D002118:Calcium; D002746:Chlorpromazine; D009638:Norepinephrine